BioCentury | Mar 11, 2021
Deals

March 10 Quick Takes: Eddy Wu’s Arctic Vision raises $100M; plus Touchlight, NeoPhore, MediciNova-BARDA and Neurelis

...mismatch repair pathway (MMR) to stimulate neoantigen generation based on discoveries originated at University of Turin.MediciNova...
...Phosphodiesterase-10 BC Staff Ketas, ibudilast (AV411, MN-166, AV-411) Arctic Vision (Shanghai) Biotechnology Co. Ltd. Loyal Valley Capital Touchlight Genetics Ltd. NeoPhore Ltd. MediciNova Inc. U.S...
BioCentury | Mar 5, 2021
Product Development

March 4 COVID Quick Takes: More guidance on vaccines for variants; plus EMA begins review of Sputnik V, Novartis-CureVac, Bharat-Ocugen, Novavax and more

...syndrome (ARDS). A 50% mortality reduction was observed at the 28-day and the 60-day time points. MediciNova...
...Golovin NVX-CoV2373 Covaxin (BBV152) CVnCoV Sputnik V (Gam-COVID-Vac) APL-9 Brii Biosciences Novavax Inc. University of Birmingham Medical Research Council Quidel Corp. Ocugen Inc. Bharat Biotech International Ltd. Cerecor Inc. MediciNova Inc. Mie...
BioCentury | Jan 30, 2021
Product Development

ALS looks up as clinical pipeline explodes

...a mAb against CD14; and Ketas ibudilast, to which MediciNova Inc....
BioCentury | Apr 10, 2020
Product Development

COVID-19 roundup: New immune targets to address pandemic; plus updates from CanSino, Arcturus, Fujifilm and more

...in patients with hypoxemia secondary to systemic inflammatory response syndrome due to acute pancreatitis. Meanwhile, MediciNova Inc....
...AV411, MN-166, AV-411) Avigan, favipiravir (T-705) Biohaven Pharmaceutical Holding Co. Ltd. Chembio Diagnostics Inc. Stony Brook University CalciMedica Inc. Thomas Jefferson University MediciNova Inc. CanSino...
BioCentury | Jul 12, 2019
Company News

MediciNova gets bounce after revealing clinical plan for MS therapy

...clarity on a clinical plan for a single Phase III study, investors appeared satisfied with MediciNova's...
...for a differentiated patient population following the approval of two other new therapies this year. MediciNova Inc....
...candidate, an oral small molecule inhibitor of PDE-4, PDE-10 and MIF that suppresses pro-inflammatory cytokines. MediciNova...
BioCentury | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

...disease (HD) Preclin Cytokines/Chemokines Macrophage migration inhibitory factor (MIF) Kyorin Pharmaceutical Co. Ltd. (Tokyo:4569) / MediciNova Inc....
BioCentury | Feb 12, 2019
Distillery Therapeutics

Neurology

...in schizophrenia. Bristol-Myers Squibb Co. markets Buspar buspirone, a 5-HT1A receptor partial agonist, for anxiety. MediciNova Inc....
BioCentury | May 4, 2018
Clinical News

MediciNova reports additional Phase Ib/IIa data for ibudilast in ALS

...open-label extension. Data were presented at the American Academy of Neurology meeting in Los Angeles. MediciNova...
...discuss next steps with FDA (see BioCentury, Aug. 8, 2016 & Feb. 2, 2018) . MediciNova...
...inhibitor of phosphodiesterase-4 (PDE-4), PDE-10 and macrophage migration inhibitory factor (MIF) that suppresses pro-inflammatory cytokines. MediciNova Inc....
BioCentury | May 4, 2018
Clinical News

MediciNova reports additional Phase IIb data for ibudilast in MS

...Data were presented at the American Academy of Neurology meeting in Los Angeles. Last year, MediciNova...
...is preparing for an end-of-Phase II meeting with FDA (see BioCentury, Nov. 3, 2017) . MediciNova...
...inhibitor of phosphodiesterase-4 (PDE-4), PDE-10 and macrophage migration inhibitory factor (MIF) that suppresses pro-inflammatory cytokines. MediciNova Inc....
BioCentury | Apr 6, 2018
Clinical News

MediciNova's tipelukast meets in Phase IIa for liver disease

...safety, pharmacokinetics, HDL-C, LDL-C, total cholesterol, liver enzymes and percentage of fat in the liver. MediciNova...
...ALOX5; 5-LO). It has Fast Track designation in the U.S. to treat NASH with fibrosis. MediciNova Inc....
...fat in the liver Status: Phase IIa data Milestone: NA Jennie Walters tipelukast (MN-001, kca-757) Kyorin Pharmaceutical Co. Ltd. MediciNova Inc. 5-lipoxygenase...
Items per page:
1 - 10 of 186
BioCentury | Mar 11, 2021
Deals

March 10 Quick Takes: Eddy Wu’s Arctic Vision raises $100M; plus Touchlight, NeoPhore, MediciNova-BARDA and Neurelis

...mismatch repair pathway (MMR) to stimulate neoantigen generation based on discoveries originated at University of Turin.MediciNova...
...Phosphodiesterase-10 BC Staff Ketas, ibudilast (AV411, MN-166, AV-411) Arctic Vision (Shanghai) Biotechnology Co. Ltd. Loyal Valley Capital Touchlight Genetics Ltd. NeoPhore Ltd. MediciNova Inc. U.S...
BioCentury | Mar 5, 2021
Product Development

March 4 COVID Quick Takes: More guidance on vaccines for variants; plus EMA begins review of Sputnik V, Novartis-CureVac, Bharat-Ocugen, Novavax and more

...syndrome (ARDS). A 50% mortality reduction was observed at the 28-day and the 60-day time points. MediciNova...
...Golovin NVX-CoV2373 Covaxin (BBV152) CVnCoV Sputnik V (Gam-COVID-Vac) APL-9 Brii Biosciences Novavax Inc. University of Birmingham Medical Research Council Quidel Corp. Ocugen Inc. Bharat Biotech International Ltd. Cerecor Inc. MediciNova Inc. Mie...
BioCentury | Jan 30, 2021
Product Development

ALS looks up as clinical pipeline explodes

...a mAb against CD14; and Ketas ibudilast, to which MediciNova Inc....
BioCentury | Apr 10, 2020
Product Development

COVID-19 roundup: New immune targets to address pandemic; plus updates from CanSino, Arcturus, Fujifilm and more

...in patients with hypoxemia secondary to systemic inflammatory response syndrome due to acute pancreatitis. Meanwhile, MediciNova Inc....
...AV411, MN-166, AV-411) Avigan, favipiravir (T-705) Biohaven Pharmaceutical Holding Co. Ltd. Chembio Diagnostics Inc. Stony Brook University CalciMedica Inc. Thomas Jefferson University MediciNova Inc. CanSino...
BioCentury | Jul 12, 2019
Company News

MediciNova gets bounce after revealing clinical plan for MS therapy

...clarity on a clinical plan for a single Phase III study, investors appeared satisfied with MediciNova's...
...for a differentiated patient population following the approval of two other new therapies this year. MediciNova Inc....
...candidate, an oral small molecule inhibitor of PDE-4, PDE-10 and MIF that suppresses pro-inflammatory cytokines. MediciNova...
BioCentury | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

...disease (HD) Preclin Cytokines/Chemokines Macrophage migration inhibitory factor (MIF) Kyorin Pharmaceutical Co. Ltd. (Tokyo:4569) / MediciNova Inc....
BioCentury | Feb 12, 2019
Distillery Therapeutics

Neurology

...in schizophrenia. Bristol-Myers Squibb Co. markets Buspar buspirone, a 5-HT1A receptor partial agonist, for anxiety. MediciNova Inc....
BioCentury | May 4, 2018
Clinical News

MediciNova reports additional Phase Ib/IIa data for ibudilast in ALS

...open-label extension. Data were presented at the American Academy of Neurology meeting in Los Angeles. MediciNova...
...discuss next steps with FDA (see BioCentury, Aug. 8, 2016 & Feb. 2, 2018) . MediciNova...
...inhibitor of phosphodiesterase-4 (PDE-4), PDE-10 and macrophage migration inhibitory factor (MIF) that suppresses pro-inflammatory cytokines. MediciNova Inc....
BioCentury | May 4, 2018
Clinical News

MediciNova reports additional Phase IIb data for ibudilast in MS

...Data were presented at the American Academy of Neurology meeting in Los Angeles. Last year, MediciNova...
...is preparing for an end-of-Phase II meeting with FDA (see BioCentury, Nov. 3, 2017) . MediciNova...
...inhibitor of phosphodiesterase-4 (PDE-4), PDE-10 and macrophage migration inhibitory factor (MIF) that suppresses pro-inflammatory cytokines. MediciNova Inc....
BioCentury | Apr 6, 2018
Clinical News

MediciNova's tipelukast meets in Phase IIa for liver disease

...safety, pharmacokinetics, HDL-C, LDL-C, total cholesterol, liver enzymes and percentage of fat in the liver. MediciNova...
...ALOX5; 5-LO). It has Fast Track designation in the U.S. to treat NASH with fibrosis. MediciNova Inc....
...fat in the liver Status: Phase IIa data Milestone: NA Jennie Walters tipelukast (MN-001, kca-757) Kyorin Pharmaceutical Co. Ltd. MediciNova Inc. 5-lipoxygenase...
Items per page:
1 - 10 of 186